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Deregulation of E2F1 activity and resistance to TGFb are hallmarks of gastric cancer. MicroRNAs (miRNAs)
are small noncoding RNAs frequently misregulated in human malignancies. Here we provide evidence that
the miR-106b-25 cluster, upregulated in a subset of human gastric tumors, is activated by E2F1 in parallel
with its host gene, Mcm7. In turn, miR-106b and miR-93 regulate E2F1 expression, establishing a miRNA-
directed negative feedback loop. Furthermore, upregulation of these miRNAs impairs the TGFb tumor sup-
pressor pathway, interfering with the expression of CDKN1A (p21Waf1/Cip1) and BCL2L11 (Bim). Together,
these results suggest that the miR-106b-25 cluster is involved in E2F1 posttranscriptional regulation and
may play a key role in the development of TGFb resistance in gastric cancer.INTRODUCTION
Although the incidence of gastric cancer declined in Western
countries from the 1940s to the 1980s, it remains a major public
health problem throughout the world, being the second most
widely diagnosed malignancy worldwide and cause of 12% of
all cancer-related deaths each year (Uemura et al., 2001). Over
95% of gastric tumors are adenocarcinomas histologically clas-
sified either as intestinal or diffuse type (Lauren, 1965). The evo-
lution of intestinal tumors has been characterized as progressing
through a number of sequential steps. Among the others, two
events are characteristic of gastric tumorigenesis: upregulation
of E2F1 (Suzuki et al., 1999) and development of TGFb resis-
tance (Ju et al., 2003; Park et al., 1994).
E2F1 is a master regulator of cell cycle that promotes the G1/S
transition transactivating a variety of genes involved in chromo-
somal DNA replication, including its own promoter (DeGregori,
2002). While overexpression of E2F1 is an oncogenic event per
se that predisposes cells to transformation (Pierce et al., 1999),
it also represents a potent apoptotic signal when occurring
over a critical threshold (Lazzerini Denchi and Helin, 2005).
On the other hand, Transforming Growth Factor-b (TGFb) is
a cytokine playing a major role within the so-called morphoge-
netic program, a complex system of crosstalk between the epi-
thelial and the stromal compartments that guides gastrointesti-
nal cells toward proliferation, differentiation, or apoptosis (van
den Brink and Offerhaus, 2007).
In this study, we explored the possibility that microRNAs
(miRNAs) may be involved in gastric tumorigenesis. miRNAs
are non-protein-coding genes thought to regulate the expression
of up to 30% of human genes, either inhibiting mRNA translation
or inducing its degradation (Lewis et al., 2005). Besides a crucialSIGNIFICANCE
MicroRNAs (miRNAs) are small noncoding RNAs that may regulate the expression of approximately 30% of all human
genes, either inhibiting target mRNA translation or inducing its degradation. These genes are abnormally expressed in hu-
man malignancies, making their biological importance increasingly apparent. Gastric cancer causes 12% of all cancer-
related deaths each year, a fact that calls for better treatments based on a deeper understanding of the molecular
mechanisms underlying the onset of this disease. Here, we show that overexpression of the miR-106b-25 cluster leads
to deregulation of important cancer-related genes, such as the TGFb effectors p21Waf1/Cip1 and Bim, disrupting the G1/S
checkpoint and conferring resistance to TGFb-dependent apoptosis.272 Cancer Cell 13, 272–286, March 2008 ª2008 Elsevier Inc.
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E2F1-Regulated miRNAs in Gastric Cancerrole in cellular differentiation and organism development (Kloos-
terman and Plasterk, 2006), miRNAs are frequently misregulated
in human cancer (Lu et al., 2005; Volinia et al., 2006), and they
can act as either potent oncogenes or tumor suppressor genes
(Esquela-Kerscher and Slack, 2006).
Here we show that E2F1 regulates miR-106b, miR-93, and
miR-25, a cluster of intronic miRNAs hosted in the Mcm7 gene,
inducing their accumulation in gastric primary tumors. Con-
versely, miR-106b and miR-93 control E2F1 expression, estab-
lishing a negative feedback loop that may be important in pre-
venting E2F1 self-activation and, possibly, apoptosis.
On the other hand, we found thatmiR-106b, miR-93, and miR-
25 overexpression causes a decreased response of gastric can-
cer cells to TGFb interfering with the synthesis of p21 and Bim,
the two most downstream effectors of TGFb-dependent cell-
cycle arrest and apoptosis, respectively. Therefore, these miRNAs
contribute to the onset of TGFb resistance in cancer cells and
may represent novel therapeutic targets for the treatment of
gastric cancer.
RESULTS
Deregulation of miRNA Expression in Human
Gastric Cancer
It is well documented that most gastric adenocarcinomas arise in
the context of a chronic inflammatory background, frequently
associated with Helicobacter pylori (HP) infection (Uemura
et al., 2001). Nevertheless, the molecular mechanisms responsi-
ble for HP oncogenicity are poorly understood, although Th1
immune response seems to be critical in the development of
preneoplastic lesions such as gastric atrophy and intestinal
metaplasia (Houghton et al., 2002; Fox et al., 2000).
In the search of miRNAs potentially involved in gastric tumor-
igenesis, we analyzed global miRNA expression in 20 gastric pri-
mary tumors of the intestinal type, each one paired with adjacent
nontumor gastric tissue from the same patient, and six gastric
cancer cell lines using a custom miRNA microarray. To identify
specific alterations associated with inflammation and/or preneo-
plastic lesions, we first compared nontumor tissues with histo-
logical signs of chronic gastritis (n = 13) versus otherwise normal
mucosa (n = 7). Seven miRNAs were associated with chronic in-
flammation by unpaired significance analysis of microarrays
(SAM), including miR-155, which is known to predispose to can-
cer (Costinean et al., 2006) and to play a major role in the regu-
lation of immune response (Rodriguez et al., 2007; Thai et al.,
2007) (Figure 1A; Table S1 available online).
We then examined the miRNA expression profile of gastric pri-
mary tumors and cancer cell lines: a total of 14 miRNAs exhibited
a 2-fold or greater median overexpression in primary tumors
compared to nontumor controls by paired SAM (Figure 1B; Table
S2). Of these, 13 out of 14 ranked above the 80th percentile in all
gastric cancer cell lines in terms of expression, except for miR-
223, which was not expressed (Table S3). Only five miRNAs
were downregulated in cancer (Figure 1B; Table S2). Microarray
data were confirmed by stem-loop qRT-PCR for nine out of ten
tested miRNAs (Table S4). Among the misregulated miRNAs,
miR-21, miR-223, miR-25, and miR-17-5p showed the highest
overexpression in tumors, with 4.5, 4.2, 3.7, and 3.7 median
fold changes, respectively.These results indicate that specific modifications in the miRNA
expression pattern are characteristic of human gastric cancer
since the earliest steps of tumorigenesis and involve miRNAs
with known oncogenic properties, such as miR-21 (Meng et al.,
2006) and miR-17-5p (He et al., 2005).
miR-106b-25 Cluster Is Overexpressed
in Gastric Cancer
Among the overexpressed miRNAs, miR-25 stood out as an at-
tractive candidate for playing a role in gastric tumorigenesis. In
fact, this was the third-most strongly upregulated miRNA in pri-
mary gastric tumors (median fold change: 3.7; range 1.0–26.8)
and ranked among the most highly expressed miRNAs in all hu-
man gastric cancer cell lines (above 97th percentile). miR-106b
(median fold change: 2.0; range 1.0–6.5) and miR-93 (median
fold change: 2.3; range 1.0–7.7) were also upregulated in primary
tumors and highly expressed in all gastric cancer cell lines
(above 82nd and 89th percentile, respectively).
These three miRNAs (hereafter miR-106b-25) are clustered in
the intron 13 ofMcm7 on chromosome 7q22 and actively cotran-
scribed in the context of Mcm7 primary RNA transcript (Kim and
Kim, 2007; Figures 1C–1E). Several studies reported the amplifi-
cation of this region in gastric tumors (Weiss et al., 2004; Peng
et al., 2003; Takada et al., 2005). However, we could not detect
any amplifications of themiR-106b-25 locus in our samples (data
not shown), implying that other mechanisms must contribute to
miR-106b-25 overexpression in gastric cancer.
Mcm7 plays a pivotal role in the G1/S phase transition, orches-
trating the correct assembly of replication forks on chromosomal
DNA and ensuring that all the genome is replicated once and not
more than once at each cell cycle (Blow and Hodgson, 2002). As
overexpression of Mcm7 has been associated with bad progno-
sis in prostate and endometrial cancer (Ren et al., 2006; Li et al.,
2005), we hypothesized that Mcm7 oncogenicity may be linked,
at least in part, to overexpression of the hosted miRNAs. More-
over, the miR-106b-25 cluster shares a high degree of homology
with themiR-17-92 cluster (Figure 1C), which appears to have an
oncogenic role (He et al., 2005; O’Donnell et al., 2005; Dews
et al., 2006).
These observations led us to pursue the miR-106b-25 cluster
as an interesting target for further studies. Given the possibility
of cross-hybridization between homolog miRNAs, we first de-
termined the specificity of stem-loop qRT-PCR. Primers for
miR-106b, miR-93, and miR-25 were highly specific, while
miR-17-5p and miR-92 probes cross-hybridized with miR-
106a and miR-25, respectively (Figure S1A). Next, we used
stem-loop qRT-PCR to assay the expression of mature miRNA
species in an independent set of ten gastric primary tumors
paired with nontumor gastric mucosa from the same patient.
Mature miR-106b, miR-93, and miR-25 were overexpressed in
6/10, 6/10, and 5/10 of these tumors, respectively, although
there was not reciprocal correlation in their level of expression
(Figure S1B).
To shed more light on this aspect, we examined miRNA pre-
cursor levels in the same tumors by conventional qRT-PCR
(Figure S1C) and we found miR-106b, miR-93, and miR-25 pre-
cursor species to be concordantly expressed in the tumors
[r(106b/93) = 0.93; r(106b/25) = 0.78; r(93/25) = 0.88; Table S5].
Of the five tumors overexpressing miR-106b-25 precursors,Cancer Cell 13, 272–286, March 2008 ª2008 Elsevier Inc. 273
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E2F1-Regulated miRNAs in Gastric CancerFigure 1. Alteration of miRNA Expression in Chronic Gastritis and Gastric Adenocarcinoma
(A and B) miRNAs significantly associated with either chronic gastritis (A) or gastric adenocarcinoma (B) by SAM analysis (FDR = 0%, q = 0). Red and green colors
indicate upregulation and downregulation, respectively. Representative histological features of normal gastric mucosa, chronic gastritis, and gastric adenocar-
cinoma are shown with hematoxylin & eosin (H&E) staining.
(C) Schematic representation of the miR-106b-25 cluster genomic locus hosted in the intron 13 ofMcm7. The primary transcript of this gene contains all the three
miRNAs fused into a unique molecule that we retrotranscribed, amplified, and sequenced from Snu-16 cells using two different sets of primers (#1 and #2).
(D and E) This molecule is not just a byproduct ofMcm7 transcription, as downregulation of Drosha by RNAi (D) induced a dramatic accumulation of this transcript274 Cancer Cell 13, 272–286, March 2008 ª2008 Elsevier Inc.
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miR-93, and miR-25 whereas the remaining tumors displayed
variable expression of each mature miRNA, suggesting an addi-
tional level of posttranscriptional regulation controlling individual
miRNAs.
Mcm7 mRNA was also overexpressed in 5/10 tumors, show-
ing an almost perfect correlation with miR-106b, miR-93, and
miR-25 precursor levels (r = 0.98, 0.92, 0.72, respectively;
Figure S1C and Table S5).
Taken together, these data argue that miR-106b-25 precur-
sors are specifically overexpressed in a subset of gastric primary
tumors in parallel with Mcm7 mRNA. Although we cannot ex-
clude the possibility of a miR-106b-25-independent promoter,
our results strongly suggest that miR-106b-25 transcription in
gastric tumors is driven by its host gene, Mcm7. Moreover,
a posttranscriptional mechanism also plays a major role in deter-
mining the levels of mature miR-106b-25, as recently proposed
for other miRNAs (Thomson et al., 2006).
A Negative Feedback Loop Controls E2F1
andmiR-106b-25 Expression
E2F1 is a transcription factor that transactivates a variety of
genes involved in chromosomal DNA replication (Johnson and
DeGregori, 2006), including Mcm7 (Suzuki et al., 1998; Arata
et al., 2000). Therefore, we hypothesized that miR-106b-25 tran-
scription may be similarly regulated by E2F1. To test this hypoth-
esis, we first determined whether endogenous fluctuations in
E2F1 protein levels corresponded to similar changes in Mcm7
and miR-106b-25 expression. Interestingly, AGS gastric cancer
cells, arrested in mitosis by nocodazole treatment for 12 hr, did
not express E2F1 protein and showed reduction in Mcm7 tran-
script (2-fold) and miR-106b, miR-93, and miR-25 precursors
(4.0-, 5.2-, and 12.0-fold, respectively), compared to exponen-
tially growing cells. As cells were released and re-entered the
G1 phase, E2F1 expression paralleled Mcm7, miR-106b, miR-
93, and miR-25 precursor RNA reaccumulation. (Figures 2A–
2C). This process was directly associated with E2F1 expression
because its specific overexpression by adenoviral transduction
(Figure 2D) or silencing by RNA interference (Figure 2E) also in-
duced consistent changes in miR-106b-25 precursor levels. Im-
portantly, E2F1 loss of function impacted the expression of ma-
ture miRNAs after 72 hr as well (Figure 2F).
To further validate our data in vivo, we analyzed E2F1 protein
expression in ten primary gastric tumors by western blot, and we
found a positive correlation between E2F1 protein and Mcm7/
miR-106b-25 precursor expression (Figure 2G). In fact, four out
of five tumors overexpressing E2F1 displayed higher levels of
Mcm7 andmiR-106b-25 precursors (Figure S1C). Of these, three
tumors also overexpressed mature miR-106b, miR-93, and miR-
25 (Figure S1B). However, one tumor showed Mcm7 and miR-
106b-25 precursor upregulation without detectable levels of
E2F1, suggesting that other transcription factors are also in-
volved in the regulation of miR-106b-25.
These results indicate that E2F1 regulates miR-106b-25 ex-
pression in parallel with Mcm7, supporting the hypothesis thatoverexpression of these miRNAs in gastric cancer is due, at least
in part, to E2F1 upregulation.
Recently, miR-17-5p has been proposed as a posttranscrip-
tional regulator of E2F1 (O’Donnell et al., 2005). Given the similar-
ity between miR-17-5p, miR-106b, and miR-93 sequences, we
explored the possibility that alsomiR-106b andmiR-93may par-
ticipate in the regulation of E2F1 expression. Because these
miRNAs were diffusely expressed in a panel of 12 gastric cancer
cell lines analyzed by qRT-PCR (Figure 3A), we adopted a loss-
of-function approach to antagonize miR-106b-25. Transfection
of LNA antisense oligonucleotides (ASOs) against miR-106b
and miR-93 induced an accumulation of E2F1 protein in Snu-
16 cells, indicating that endogenous levels of these miRNAs con-
trol its expression (Figure 3B). Also, overexpression of these
miRNAs by either oligonucleotide transfection or lentiviral trans-
duction (Figure S1D) clearly decreased E2F1 protein levels in
Snu-16 and AGS gastric cancer cell lines (Figures 3C and 3D)
and inhibited the expression of a reporter vector containing
E2F1 30UTR. Mutation of the predicted miRNA binding sites in
the reporter vector abrogated this effect, indicating that miR-
106b and miR-93 directly interact with E2F1 30UTR (Figure 3E).
However, E2F1 mRNA decreased by 2-fold upon miR-106b
andmiR-93 transfection, possibly because of partial mRNA deg-
radation or downmodulation of E2F1 transcriptional activators
(Figure 3F).
It has been argued that miR-17-5p may secondarily inhibit
E2F1 expression by suppressing AIB-1 protein that in fact acti-
vates E2F1 transcription and is also a miR-17-5p target (Hossain
et al., 2006). While it is very reasonable that miRNAs act on dif-
ferent targets within the same pathway, we analyzed AIB-1 pro-
tein levels in AGS and Snu-16 cells and found a slight decrease
or no difference at all in cells transfected with either miR-106b or
miR-93, respectively, suggesting that AIB-1 is a bona fide low-
affinity target of miR-106b that may only partially contribute to
E2F1 downregulation (Figure 3C).
Together, these results show that E2F1 regulates miR-106b-
25 expression but is also a target of miR-106b and miR-93,
establishing a negative feedback loop in gastric cancer cells.
Because E2F1 is known to self-activate its own promoter
through a positive feedback loop, these miRNAs may control
the rate of E2F1 protein synthesis, preventing its excessive accu-
mulation, as recently proposed for homologmiR-17-5p andmiR-
20a (Sylvestre et al., 2007; Woods et al., 2007).
miR-106b andmiR-93 Impair TGFb-Induced
Cell-Cycle Arrest
Our results thus far indicate that miR-106b-25 transcription is
promptly induced by E2F1 as cells exit mitosis and re-enter the
G1 phase. On this basis, we hypothesized a possible role for
miR-106b-25 in repressing G0/G1-associated activities, ideally
cooperating with E2F1. So, we interrogated the TargetScan da-
tabase looking for genes known to be negatively regulated by
E2F1, and we identified CDKN1A (p21) as a putative target of
miR-106b and miR-93. This gene, frequently dysfunctional in hu-
man cancer, is a key inhibitor of the cell cycle (Mattioli et al.,(E), confirming the presence of an active preliminary miRNA. Bars indicate RNA expression normalized to U6 ± SD. This cluster shares a high degree of homology
with miR-17-92 and miR-106a-92 clusters, located on chromosomes 13 and X, respectively. Colors identify miRNAs of the same family.
Cancer Cell 13, 272–286, March 2008 ª2008 Elsevier Inc. 275
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(A–C) (A) FACS analysis of AGS cells synchronized in mitosis by nocodazole treatment for 12 hr and subsequently released in fresh medium. Cells were harvested
at different time points and analyzed for E2F1 protein content by western blot (B) and Mcm7, miR-106b, miR-93, and miR-25 precursor RNA levels by qRT-PCR276 Cancer Cell 13, 272–286, March 2008 ª2008 Elsevier Inc.
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dogenously expressed in Snu-16 cells posttranscriptionally reg-
ulate p21. In fact, their inhibition by ASOs enhanced the expres-
sion of p21 protein (Figure 4A). Conversely, upregulation of miR-
106b andmiR-93 achieved by either oligonucleotide transfection
(Figure 4B) or lentiviral transduction (Figure 4C) repressed p21
protein expression without significant changes in p21 mRNA
levels (Figure 4D). Moreover, miR-106b and miR-93 mimics in-
hibited the expression of a reporter vector containing p21
30UTR, while mutation of the predicted miRNA-binding site abro-
gated this effect (Figure 4E).
Given the importance of p21 in the regulation of cell cycle, we
decided to address the role of miR-106b-25 in controlling the
proliferation of gastric cancer cells. Unexpectedly, loss of miR-
106b, miR-93, and/or miR-25 function induced by ASO transfec-
tion did not produce any significant alterations in the cell cycle
and proliferation of Snu-16 cells (Figures S2A and S2C). Simi-
larly, overexpression of the three miRNAs by either oligonucleo-
tide transfection or lentiviral transduction did not significantly
modify the proliferation rate and colony formation efficiency of
AGS cells, although we noticed limited but reproducible cell-
cycle perturbations upon miR-93 overexpression (+8% of cells
in S phase; Figures S2B, S2D, and S2E). We obtained similar
results using GTL-16 and MKN-74 gastric cancer cell lines
(data not shown), indicating that miR-106b-25 function is not
essential for the survival and the proliferation of gastric cancer
cells in vitro. However, specific silencing of either p21 or E2F1
by RNAi produced no significant alterations in the proliferation
as well (Figures S2G and S2H), confirming that these cancer
cell lines are not responsive to p21 basal levels and can well
compensate for the loss of E2F1 expression.
Therefore, we decided to address the role of miR-106b-25 in
the presence of TGFb: this cytokine, by inducing the expression
of p21 and other antiproliferative molecules, ensures timely co-
ordinated cell-cycle arrest and apoptosis of mature cells in the
gastrointestinal tract, thus controlling the physiological turnover
of epithelial cells (van den Brink and Offerhaus, 2007). Impair-
ment of this crucial tumor suppressor pathway is a hallmark of
gastric cancer (Ju et al., 2003; Park et al., 1994). However,
Snu-16 cells are among the few gastric cancer cell lines still re-
sponding to relatively high doses of TGFb in vitro, undergoing
G1/S arrest and subsequent massive apoptosis (Ohgushi et al.,
2005 and Figure 5A). Nevertheless, cell viability decreases after
24 hr, thus opening a window to study early molecular changes
associated with TGFb.
Interestingly, stimulation with TGFb induced marked downre-
gulation of E2F1 protein, Mcm7 mRNA, and miR-106b-25 pre-
cursors after 16 hr, when cells physiologically undergo G1/S ar-
rest, suggesting that downmodulation of these miRNAs is part of
the physiological response to TGFb (Figures 5B and 5C). To es-
tablish the importance of this process, we counteracted miR-106b-25 downregulation by introducing miR-106b, miR-93,
and/or miR-25 mimics in Snu-16 cells in the presence of TGFb.
Notably, overexpression of miR-93 completely abrogated
TGFb-induced cell-cycle arrest, while miR-106b partially de-
creased it (p < 0.0002), consistent with the degree of p21 down-
regulation induced by these miRNAs (Figure 5D). Conversely, an-
tagonizing endogenous miR-106b and miR-93 expression by
ASOs significantly increased the number of Snu-16 cells under-
going TGFb-dependent cell-cycle arrest (p < 0.0013) and re-
stored sensitivity to suboptimal doses of TGFb (p < 0.0001), to
which these cells are otherwise resistant (Figures 6A and 6B).
Accordingly, the degree of p21 upregulation achieved by inhibit-
ing endogenous miR-106b and miR-93 in the presence of TGFb
(Figure 6C) was double than that in basal conditions (Figure 4A),
probably supported by the active transcription of p21 mRNA
(Figure 6D).
To establish the role of p21 in inducing the phenotype associ-
ated with miR-106b and miR-93 gain/loss of function, we specif-
ically silenced p21 by RNAi (si-p21) in Snu-16 cells treated with
TGFb. This recapitulated almost in full the effect of miR-106b
andmiR-93 overexpression on cell-cycle distribution (Figure 5D),
whereas cotransfection of si-p21 with miR-106b and miR-93
dramatically reduced the effect of these miRNAs on TGFb-in-
duced cell-cycle arrest, suggesting that p21 is a primary target
in this biological context (Figure 6E). However, a small but statis-
tically significant effect on TGFb-dependent cell-cycle arrest by
miR-93 was still observable in the absence of p21 (p = 0.0272),
implying that other direct or indirect targets cooperate with
p21. Analysis of expression for genes involved in the G1/S
checkpoint points at p27 as a possible indirect target of miR-
93 (Figure 6F).
From these data we conclude thatmiR-106b andmiR-93 inter-
fere with TGFb-induced cell-cycle arrest, mainly inhibiting the
expression of p21 at the posttranscriptional level. However,
p21-independent pathways may be also involved in delivering
the complete effect of miR-93 on cell-cycle control.
miR-25 Cooperates withmiR-106b andmiR-93
in Preventing the Onset of TGFb-Induced Apoptosis
Our results so far support a role for miR-106b and miR-93 in
modulating the cell-cycle arrest in the early phase of TGFb stim-
ulation. At this point, we decided to analyze miR-106b-25 func-
tion upon prolonged exposure to TGFb that eventually results in
apoptosis (Ohgushi et al., 2005, and Figure 5B).
To this aim, we examined the viability of Snu-16 cells stimu-
lated with TGFb for 24–48 hr by tetrazolium reduction assay. In-
terestingly, introduction of miR-106b, miR-93, and/or miR-
25 mimics in these cells induced marked resistance to TGFb
(Figure 7A). Conversely, ASO transfection induced a negative
trend in the number of viable cells that reached statistical signif-
icance (p = 0.003) when all the three miRNAs were inhibited at(C). Each analysis was performed in triplicate. Bars indicate RNA expression normalized to U6 ± SD.
(D) AGS cells were plated at 90% confluence and starved in 0.5% FBS RPMI 1640 medium for 36 hr. Cells were then infected with either adeno-GFP or adeno-
E2F1 viruses at an moi of 25 and incubated for an additional 21 hr: at this time, cells displayed no signs of apoptosis, as determined by morphology, trypan-blue
staining, and analysis of subdiploid DNA content (data not shown). miR-106b, miR-93, and miR-25 precursors were measured by qRT-PCR as above.
(E and F) Snu-16 cells were transfected with a siRNA against E2F1 (100 nM), and expression of miR-106b-25 precursor (E) and mature (F) species was determined
after 72 hr by qRT-PCR, as above. Bars indicate RNA expression normalized to U6 ± SD.
(G) Expression of E2F1 protein in the same gastric primary tumors presented in Figure S1. Red circles indicate overexpression of Mcm7 and miR-106b-25 pre-
cursor RNA in the corresponding tumors, as determined by qRT-PCR.Cancer Cell 13, 272–286, March 2008 ª2008 Elsevier Inc. 277
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E2F1-Regulated miRNAs in Gastric CancerFigure 3. E2F1 Is a Target of miR-106b and miR-93
(A) Endogenous expression of mature miR-106b,miR-93, and miR-25 in human gastric cancer cell lines and normal mucosa determined by stem-loop qRT-PCR;
bars indicate RNA expression normalized to U6 ± SD. Snu-1 cells are thought to derive from a gastric neuroendocrine tumor (NET), while RF1 and RF48 cells are
from a B cell lymphoma of the stomach. All the other cell lines are from gastric adenocarcinoma.
(B–D) Western blot of Snu-16 cells 48 hr after inhibition of miR-106b and miR-93 by ASO transfection (B) or overexpression of the same miRNAs by oligonucle-
otide transfection (C) or lentiviral transduction (D). Scramble RNA or LNA oligonucleotides were used as negative control. Protein expression was quantified and
normalized to GAPDH. Similar results were obtained in AGS and MKN-74 cells (data not shown).
(E) Luciferase assay showing decreased luciferase activity in cells cotransfected with pGL3-E2F1-30UTR and miR-106b or miR-93 oligonucleotides. Deletion of
the first three bases in three putative miR-106b/miR-93 binding sites, complementary to miRNA seed regions, abrogates this effect (MUT). Bars indicate Firefly
luciferase activity normalized to Renilla luciferase activity ± SD. Each reporter plasmid was transfected at least twice (on different days), and each sample was
assayed in triplicate.
(F) qRT-PCR analysis showing E2F1 mRNA downregulation in the same cells presented in (C). Bars indicate RNA expression normalized to U6 ± SD.278 Cancer Cell 13, 272–286, March 2008 ª2008 Elsevier Inc.
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E2F1-Regulated miRNAs in Gastric CancerFigure 4. miR-106b and miR-93 Repress p21 Protein Expression
(A–C) P21 expression in Snu-16 cells grown in 0.5% FBS RPMI 1640 after transfection with either miR-106b and miR-93 ASOs (A) or mimics (B) or upon lentiviral
transduction of the same miRNAs (C).
(D) qRT-PCR results showing no significant difference in p21 mRNA levels in Snu-16 cells transfected with either miR-106b or miR-93 oligonucleotides. Bars
indicate RNA expression normalized to U6 ± SD.
(E) Reporter assay showing decreased luciferase activity in cells cotransfected with pGL3-p21-30UTR and miR-106b or miR-93 oligonucleotides. Deletion of the
first three bases of miR-106b/miR-93 predicted binding site, complementary to miRNA seed regions, abrogates this effect (MUT). Bars indicate Firefly luciferase
activity normalized to Renilla luciferase activity ± SD. Each reporter plasmid was transfected at least twice (on different days), and each sample was assayed in
triplicate.the same time (Figure 7B). This result was confirmed by FACS
analysis that showed a significant increase in the number of sub-
diploid cells upon silencing of the three miRNAs (p < 0.001).
Moreover, the higher sensitivity of this assay allowed detection
of smaller but significant changes (p < 0.001) in the percentage
of subdiploid cells upon individual inhibition of miR-106b, miR-
93, or miR-25 (Figure 7C). Finally, silencing of miR-106b-25 par-
tially restored sensitivity to TGFb in otherwise resistant MKN-74
cells (Figure S3). Together, these results are consistent with
a model where endogenous miR-106b, miR-93, and miR-25 co-
operate in modulating the expression of one or more targets me-
diating TGFb-dependent apoptosis.
Thus, we searched TargetScan database looking for effectors
of apoptosis, and we identified BCL2L11 (Bim) as the only strong
candidate out of 18 human genes harboring putative binding
sites for miR-106b, miR-93, and miR-25 at the same time (Table
S6). Bim is a BH3-only protein that critically regulates apoptosis
in a variety of tissues by activating proapoptotic molecules like
Bax and Bad and antagonizing antiapoptotic molecules likeBcl2 and BclXL (Gross et al., 1999). A fine balance in the intracel-
lular concentrations of Bim and its partner proteins is crucial in
order to properly regulate apoptosis. As a matter of fact, Bim is
haploinsufficient, and inactivation of even a single allele acceler-
ates Myc-induced development of tumors in mice without loss of
the other allele (Egle et al., 2004). Notably,Bim is the most down-
stream apoptotic effector of the TGFb pathway, and its downmo-
dulation abrogates TGFb-dependent apoptosis in Snu-16 cells
(Ohgushi et al., 2005).
Thus, we wanted to verify whether Bim was a direct target of
miR-106b-25. Snu-16 cells express all the three major isoforms
of Bim, namely Bim EL, Bim L, and Bim S. Intriguingly, antag-
onizing endogenous miR-25 by ASO transfection induced an
accumulation of all the three isoforms in Snu-16 cells, whereas
miR-25 overexpression by either oligonucleotide transfection
or lentiviral transduction reduced their expression. On the
contrary, miR-106b and miR-93 did not influence Bim expres-
sion in three out of three tested gastric cancer cell lines
(Figure 7D).Cancer Cell 13, 272–286, March 2008 ª2008 Elsevier Inc. 279
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E2F1-Regulated miRNAs in Gastric CancerFigure 5. Overexpression of miR-106b and miR-93 Interfere with TGFb-Dependent G1/S Cell-Cycle Arrest
(A) Physiological response of Snu-16 cells to 1 ng/ml TGFb: in the early phases of stimulation (16 hr), cells undergo a G1/S cell-cycle arrest, while apoptosis is still
limited, as determined by subdiploid DNA content. The number of cells undergoing apoptosis progressively increases in the following hours.
(B and C) Downregulation of E2F1 protein (B) and Mcm7, miR-106b, miR-93, and miR-25 precursors (C) 16 hr after TGFb stimulation. Bars indicate RNA expres-
sion normalized to U6 ± SD.
(D) Snu-16 cells were transfected with the indicated oligonucleotides and treated with 1 ng/ml TGFb after 12 hr. (Upper panel) p21 protein expression. (Bottom
panel) FACS analysis, comparison of G1/S fractions between mock- and miRNA-transfected cells using unpaired Student’s t test.While it is still possible that miR-106b and miR-93 cooperate
with miR-25 in regulating Bim expression in other tissues, this
supports a model where multiple effectors of apoptosis are co-
ordinately repressed by each of the three miRNAs in gastric can-
cer.
Therefore, we decided to focus on Bim as one of these ap-
optotic effectors, and we determined that miR-25 predicted
binding sites on its 30UTR mediate target recognition and
subsequent inhibition of translation by luciferase assay
(Figure 7E). Moreover, Bim EL and Bim L mRNA levels were280 Cancer Cell 13, 272–286, March 2008 ª2008 Elsevier Inc.
Cancer Cell
E2F1-Regulated miRNAs in Gastric Cancerunchanged in Snu-16 cells uponmiR-25overexpression, which is
indicative of a posttranscriptional regulatory mechanism (Fig-
ure 7F).
In order to establish the importance of Bim downregulation
relative to miR-25-specific antiapoptotic function, we sup-
pressed Bim protein in Snu-16 cells using a siRNA against its
three major isoforms (si-Bim, Figure 7D), and we subsequently
treated these cells with TGFb for 24 hr. Notably, protection
from apoptosis conferred by si-Bim andmiR-25was very similar,
as determined by subdiploid DNA content and Annexin V stain-
ing. Moreover, cotransfection of Bim and miR-25 did not have
significant additive effects (p = 0.6328), suggesting that Bim
downregulation is a main mechanism of resistance to TGFb-in-
duced apoptosis in miR-25-overexpressing cells (Figure 7G and
Figure S4).
In conclusion, we provide evidence that miR-106b-25 cluster,
activated by E2F1 and upregulated in human gastric adenocar-
cinomas, alters the physiological response of gastric cancer
cells to TGFb, affecting both cell-cycle arrest and apoptosis (Fig-
ure 8). These findings are of particular relevance in a gastric can-
cer model, as impairment of the TGFb tumor suppressor path-
way is a critical step in the development of gastric tumors.
DISCUSSION
In this study we performed a genome-wide analysis of miRNA
expression in different steps of gastric carcinogenesis. Since
the vast majority of gastric tumors originate from a chronic in-
flammatory background (Uemura et al., 2001), we considered
of particular relevance discriminating between preneoplastic
and tumor-specific alterations. Here, we identified the specific
overexpression of a miRNA cluster in human tumors that had
been ignored thus far. Although we focused on gastric cancer,
overexpression of miR-106b, miR-93, and miR-25 in other types
of cancer may be a common, yet underestimated, event. In fact,
miR-106b-25 expression is intimately linked with the expression
of E2F1 and Mcm7 that is involved in basic mechanisms of cel-
lular proliferation. For example, Mcm7 is frequently overex-
pressed in prostate cancer (Ren et al., 2006), and in fact, we
previously described miR-25 upregulation in a large-scale
miRNA study on this type of cancer (Volinia et al., 2006). More-
over, we showed that stem-loop qRT-PCR probes commonly
used in assaying the expression of miR-92, which is overex-
pressed in most human tumors (Volinia et al., 2006), cross-
hybridize with miR-25. However, given the nearly identical
sequences, it is very likely that miR-106b-25 and miR-17-92 co-
operate in exerting similar, if not identical, functions: in fact, we
found that miR-17-5p, miR-18a, and miR-20a also inhibit p21
expression, whereas miR-92 represses Bim expression (F.P.
and A.V., unpublished data). Moreover, both miR-106b-25 and
miR-17-92 are regulated by E2F1. These clusters also exhibit
some differences, though. For example, miR-106b resembles
miR-17-5p but it is three nucleotides shorter: it has been re-
ported that specific sequences in the 30 termini can define the
intracellular localization of miRNAs (Hwang et al., 2007). More-
over, the miR-19 family is not represented in the miR-106b-25
cluster (Figure 2A).
On the other hand, miR-93 belongs to the same family of miR-
372 and miR-373: these miRNAs are overexpressed in testiculargerm cell tumors where they impair LATS2 expression, making
cells insensitive to high p21 levels (Voorhoeve et al., 2006). In
our study, miR-93 acts within the same pathway, directly target-
ing p21 expression. Therefore, this family of miRNAs seems to be
involved in the control of a crucial hub for the regulation of cell
cycle and may have particular relevance in cancer. Moreover,
miR-93 shares high sequence homology with miR-291-3p,
miR-294, andmiR-295: these miRNAs are specifically expressed
in pluripotent ES cells, and they are either silenced or downregu-
lated upon differentiation (Houbaviy et al., 2003). Given our re-
sults, we speculate that these miRNAs may be similarly involved
in the regulation of p21.
From this and previous studies, it is becoming clear that
miRNAs play a role in the control of cell cycle through different
mechanisms. In the case of E2F1, miRNAs seem to act mainly
in the context of regulatory, redundant feedback loops. In fact,
miR-106b, miR-93, miR-17-5p, and miR-20a, located on sepa-
rate miRNA clusters, are regulated by E2F1 and presumably
cooperate in inhibiting its translation. Whether miRNAs are
essential in determining temporal regulation of E2F1 expression
is still unclear and deserves further studies.
At the same time, we found these miRNAs to be involved in the
control of p21 expression and early response to TGFb. Although
we focused on the TGFb tumor suppressor pathway, it is conceiv-
able that they also control other tumor suppressor pathways con-
verging onp21. Loss ofp21 function by mutation, deletion, hyper-
methylation, ubiquitination, or mislocalization is a frequent event
and a negative prognostic factor in human gastric cancer (Mattioli
et al., 2007). However, the role of miRNAs in p21 regulation has
not yet been reported. Since 80% of our gastric primary tumors
did not express p21protein at detectable levels, we could not es-
tablish an inverse correlation between miRNAs and p21 protein
expression. However, p21 mRNA levels in primary tumors were
often comparable to normal tissues, indicating posttranscrip-
tional regulation as a frequent cause of p21 downregulation in
gastric cancer (F.P and A.V., unpublished data).
Interestingly, induction of p21 expression seemed to be a pre-
requisite to elicit amiR-106b/miR-93-associated response in the
early phase of TGFb stimulation. Conversely, silencing p21 by
RNAi dramatically decreased the effect of these miRNAs on
cell cycle. Although hundreds of different targets are predicted
for each miRNA by computational methods, there is increasing
evidence that ‘‘primary miRNA targets’’ may be critical for spe-
cific biological functions. For example, miR-10b enhances cell
motility and invasiveness of breast cancer cells, but this pheno-
type is completely reverted upon constitutive expression of its
target HOXD10, although over 100 targets are predicted for
this miRNA (Ma et al., 2007). Of course, these observations do
not exclude other contexts where parallel regulation of multiple
targets by a single miRNA is necessary to exert a specific func-
tion. Furthermore, it is also conceivable that multiple miRNAs co-
operate in exerting the same function.
This is the case of the miR-106b-25 cluster that protects gas-
tric cancer cells from apoptosis. Such effect is partitioned be-
tween the three miRNAs that cooperate in repressing the expres-
sion of different proapoptotic molecules. We identified Bim, the
most downstream apoptotic effector of the TGFb pathway (Oh-
gushi et al., 2005), as a key target of miR-25. This is of particular
relevance in a gastric cancer model. In fact, TGFb is one of theCancer Cell 13, 272–286, March 2008 ª2008 Elsevier Inc. 281
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E2F1-Regulated miRNAs in Gastric CancerFigure 6. Inhibition of Endogenous miR-106b and miR-93 Expression Enhances TGFb-Dependent G1/S Cell-Cycle Arrest
(A) Analysis of cell cycle in Snu-16 cells treated with TGFb upon inhibition of endogenous miRNAs by ASO transfection. p value was calculated comparing the G1
fraction in ASO transfected cells versus mock-transfected cells (unpaired Student’s t test).
(B) Dose-response curve of Snu-16 treated with graded doses of TGFb ranging from 0.1 to 5.0 ng/ml. Inhibition of endogenous miR-106b or miR-93 by ASO
transfection restores sensitivity of Snu-16 cells to TGFb doses to which they are otherwise resistant (0.1–0.3 ng/ml), as determined by FACS analysis. *p < 0.0001.
(C and D) Analysis of p21 protein (C) and p21 mRNA expression (D) by western blot and qRT-PCR, respectively. Bars indicate RNA expression normalized to U6 ±
SD. The degree of p21 protein upregulation induced by inhibition of endogenous miR-106b and miR-93 is greatly enhanced by the presence of TGFb, possibly
supported by the increased transcription of p21 mRNA.282 Cancer Cell 13, 272–286, March 2008 ª2008 Elsevier Inc.
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lating the physiological turnover of epithelial cells through apo-
ptosis (van den Brink and Offerhaus, 2007). While the identity
of miR-106b and miR-93 proapoptotic targets remains elusive,
we could clearly detect antiapoptotic and proapoptotic re-
sponses associated with miR-106b, miR-93, and/or miR-25
overexpression and inhibition, respectively; these properties
emerge in the late phase of TGFb stimulation when cell-cycle ar-
rest is revoked and apoptosis becomes the dominant process
characterizing the response of gastric cells to TGFb. The small
but significant alterations observed upon inhibition of single miR-
NAs, readily detected by analysis of subdiploid DNA content, ac-
quire biological consistency when the three ASOs are delivered
together, confirming the cooperative relationship between these
clustered miRNAs.
Although a negative trend was observed in TGFb-stimulated
cells transfected with single ASOs by both tetrazolium reduction
assay and analysis of subdiploid DNA content, this did not reach
statistical significance in the tetrazolium reduction assay. This is
to be imputed to the 5%–10% standard error associated with
this assay that statistically excludes smaller differences. On the
contrary, the standard error in the analysis of subdiploid DNA
content was below 2% in our hands.
When we looked at Bim expression in primary tumors, we no-
ticed general overexpression compared to normal tissues (F.P.
and A.V., unpublished data). This is consistent with previous
studies showing that Bim is induced by oncogenic stress as
a safeguard mechanism to prevent aberrant proliferation. Spe-
cifically, Bim is overexpressed in Myc transgenic mice, deter-
mining extensive apoptosis of normal cells. However, the onset
of tumors in these mice coincides with the loss of one Bim allele
that becomes insufficient. Still, Bim remains definitely overex-
pressed in tumors compared to healthy tissues that are not sub-
ject to oncogenic stress (Egle et al., 2004). Therefore, it is hard to
define a threshold below which Bim insufficiency occurs, and al-
ternative strategies are needed to define the importance of miR-
25 upregulation in vivo.
Several mechanisms have been described leading to Bim
downregulation in cancer, from transcriptional regulation to pro-
tein degradation (Yano et al., 2006; Tan et al., 2005). While all of
these mechanisms clearly contribute to Bim silencing, we pro-
pose miR-25 interference as an additional mechanism of Bim
posttranscriptional regulation in gastric cancer.
It has been extensively debated whether miRNAs are just fine-
tuning molecules or they act as key gene switches. Recent stud-
ies suggest that both hypotheses are probably true, depending
on the specific biological context. From this perspective, the
therapeutic potential of miRNAs in cancer may be strictly asso-
ciated with the occurrence of specific miRNA-dependent func-
tional alterations. Knowing the mechanisms of action of tumor-
related miRNAs will be essential in one day establishing the
molecular diagnosis of miRNA-dependent tumors, allowing the
rational selection of those patients eventually responding to
miRNA-based therapies.EXPERIMENTAL PROCEDURES
Cell Culture and Treatments
All cell lines were obtained by ATCC and cultured in RPMI 1640 medium sup-
plemented with 10% fetal bovine serum, penicillin, and streptomycin. Cells
were transfected with Lipofectamine 2000 (Invitrogen) using 100 nM miRNA
precursors (Ambion), 100 nM si-p21 (Santa Cruz), 100 nM si-Bim (Cell Signal-
ing), or 100 nM LNA miRNA antisense oligonucleotides (Exiqon). Protein ly-
sates and total RNA were collected at the time indicated. miRNA processing
and expression were verified by northern blot and stem-loop qRT-PCR. We
confirmed transfection efficiency (>95%) using BLOCK-IT Fluorescent Oligo
(Invitrogen) for all the cell lines.
For synchronization experiments, AGS cells were grown in 10% FBS RPMI
1640 containing 0.03 mg/ml nocodazole for 12 hr and subsequently released in
fresh medium. Progression through the cell cycle was followed by FACS anal-
ysis until 8 hr, after which cells rapidly lost synchronization.
For TGFb experiments, 2 3 106 Snu-16 cells were transfected in 6-well
plates in a 1:1 mixture of Optimem (GIBCO) and RPMI 1640 10% FBS (Sigma)
using 5 ml Lipofectamine 2000 and 100 nM miRNA precursors (Ambion) or LNA
antisense oligonucleotides (Exiqon). After 12 hr, medium was replaced with
RPMI 1640 10% FBS containing 1 ng/ml human recombinant TGFb1 (Sigma).
Number of viable cells was assayed using WST tetrazolium salt (CCK-8, Do-
jindo) as per the manufacturer’s instructions. All the experiments were per-
formed in triplicate. Results were expressed as mean ± SD.
qRT-PCR
Mature miRNAs and other mRNAs were assayed using the single-tube Taq-
Man MicroRNA Assays and the Gene Expression Assays, respectively, in ac-
cordance with manufacturer’s instructions (Applied Biosystems, Foster City,
CA). All RT reactions, including no-template controls and RT minus controls,
were run in a GeneAmp PCR 9700 Thermocycler (Applied Biosystems). RNA
concentrations were determined with a NanoDrop (NanoDrop Technologies,
Inc.). Samples were normalized to RNU49 or CAPN2 (Applied Biosystems),
as indicated. Gene expression levels were quantified using the ABI Prism
7900HT Sequence detection system (Applied Biosystems). Comparative
real-time PCR was performed in triplicate, including no-template controls. Rel-
ative expression was calculated using the comparative Ct method.
Luciferase Assays
MKN-74 gastric cancer cells were cotransfected in six-well plates with 1 mg of
pGL3 firefly luciferase reporter vector (see Supplemental Experimental Proce-
dures), 0.1 mg of the phRL-SV40 control vector (Promega), and 100 nM miRNA
precursors (Ambion) using Lipofectamine 2000 (Invitrogen). Firefly and Renilla
luciferase activities were measured consecutively by using the Dual Luciferase
Assay (Promega) 24 hr after transfection. Each reporter plasmid was trans-
fected at least twice (on different days) and each sample was assayed in
triplicate.
Flow Cytometry
For cell-cycle analysis, 2 3 106 cells were fixed in cold methanol, RNase-
treated, and stained with propidium iodide (Sigma). Cells were analyzed for
DNA content by EPICS-XL scan (Beckman Coulter) by using doublet discrim-
ination gating. All analyses were performed in triplicate and 20,000 gated
events/sample were counted. For apoptosis analysis, cells were washed in
cold PBS, incubated with Annexin V-FITC (BD Biopharmingen) and PI (Sigma)
for 15 min in the dark, and analyzed within 1 hr.
Statistical Analysis
Results of experiments are expressed as mean ± SD. Student’s unpaired t test
was used to compare values of test and control samples. p < 0.05 indicated
significant difference.(E) Snu-16 cells were transfected with a siRNA against p21 alone or in combination with either miR-106b or miR-93 mimics and treated with 1 ng/ml TGFb for 16
hr. While miR-106b lost all of its effect on cell cycle, miR-93 still maintained a residual effect after p21 silencing. This differential response between miR-106b and
miR-93 is statistically significant (p = 0.0272).
(F) Analysis of expression by western blot of various proteins involved in the G1/S checkpoint upon TGFb stimulation.
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E2F1-Regulated miRNAs in Gastric CancerFigure 7. miR-25 Cooperates with miR-106b and miR-93 in Preventing the Onset of TGFb-Induced Apoptosis
(A) CCK-8 viability assay of Snu-16 cells transfected with miRNA mimics. Asterisk indicates significant difference (p < 0.001) in the number of viable cells upon
transfection of miR-106b, miR-93, miR-25, and/or miR-106b-25 and subsequently treated with 1 ng/ml TGFb for 48 hr.284 Cancer Cell 13, 272–286, March 2008 ª2008 Elsevier Inc.
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E2F1-Regulated miRNAs in Gastric CancerFigure 8. The E2F1/miR-106b-25/p21 Pathway
A model summarizing the mechanism of action of miR-106,
miR-93, and miR-25 described in this study.
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